HAYWARD, Calif.--(BUSINESS WIRE)--May 28, 2008--IMPAX
Laboratories, Inc. (OTC: IPXL) today announced that due to urgent
priorities associated with the recent revocation of the registration
of the Company's common stock under section 12(g) of the Securities
and Exchange Act of 1934, the Company finds it necessary to cancel its
previously announced presentation at the UBS Global Specialty and
Generic Pharmaceuticals Conference on Thursday, May 29th, at 10:00
a.m. London GMT (5:00 a.m. ET).
About IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and markets its branded products through the IMPAX
Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully
leverage its technology platform. IMPAX Laboratories is headquartered
in Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at: www.impaxlabs.com.
CONTACT: IMPAX Laboratories, Inc.
Larry Hsu, Ph.D., President & CEO
510-476-2000, Ext. 1111
Arthur A. Koch, Jr., Sr. VP & CFO
215-933-0351
Mark Donohue, Sr. Director IR
215-933-3526
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com
www.lhai.com
SOURCE: IMPAX Laboratories, Inc.